Continuous glucose monitoring: A consensus conference of the American association of clinical endocrinologists and American College of endocrinology

Endocrine Practice

Volumn 22, Issue 8, 2016, Pages 1008-1021

  Fonseca, Vivian A ^a   Grunberger, George ^b,l,m,n   Anhalt, Henry ^c   Bailey, Timothy S ^d   Blevins, Thomas ^e   Garg, Satish K ^f   Handelsman, Yehuda ^g   Hirsch, Irl B ^h   Orzeck, Eric A ⁱ   Roberts, Victor Lawrence ^j   Tamborlane, William ^k  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Grunberger Diabetes Institute   (United States)

^c T1D Exchange   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Texas Diabetes and Endocrinology   (United States)

^f UNIVERSITY OF COLORADO DENVER   (United States)

^g Metabolic Institute of America   (United States)

^h UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

ⁱ Endocrinology Associates   (United States)

^j UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^k YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

ⁿ CHARLES UNIVERSITY   (Czech Republic)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

BLOOD GLUCOSE MONITORING; CALIBRATION; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); CONSENSUS DEVELOPMENT; CONTINUOUS GLUCOSE MONITORING SYSTEM; COST EFFECTIVENESS ANALYSIS; DIABETES CONTROL; DIABETES MELLITUS; DRUG EFFICACY; DRUG LABELING; DRUG SAFETY; ENDOCRINOLOGIST; GLUCOSE BLOOD LEVEL; GLUCOSE SENSOR; GLYCEMIC CONTROL; GLYCEMIC INDEX; GOVERNMENT; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFORMATION PROCESSING; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; MEDICAL DEVICE; MEDICAL SOCIETY; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PATIENT EDUCATION; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REIMBURSEMENT; REVIEW; SCHOOL ATTENDANCE; SELF MONITORING; STANDARDIZATION; UNITED STATES; BLOOD; CONSENSUS; ENDOCRINOLOGY; ORGANIZATION AND MANAGEMENT; QUALITY OF LIFE; STANDARDS;

BLOOD GLUCOSE SELF-MONITORING; CONSENSUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; ENDOCRINOLOGY; HUMANS; QUALITY OF LIFE;

EID: 85007547406     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP161392.CS     Document Type: Review

References (67)

1. Miller K, Foster N, Tamborlane W, Bergenstal R, Beck R. Continuous glucose monitoring in T1D patients using injections of insulin: A report from the T1D Exchange clinic registry. Diabetes Technol Ther. 2016;18:A-27. Abstract 069.
2. Davey RJ, Low C, Jones TW, Fournier PA. Contribution of an intrinsic lag of continuous glucose monitoring systems to differences in measured and actual glucose concentrations changing at variable rates in vitro. J Diabetes Sci Technol. 2010;4:1393-1399.
3. Bailey TS, Grunberger G, Bode BW, et al. American Association of Clinical Endocrinologists and American College of Endocrinology 2016 outpatient glucose monitoring consensus statement. Endocr Pract. 2016;22:231-261.
4. Kovatchev BP, Patek SD, Ortiz EA, Breton MD. Assessing sensor accuracy for non-adjunct use of continuous glucose monitoring. Diabetes Technol Ther. 2015;17: 177-186.
5. Tamborlane WV, Beck RW, Bode BW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359:1464-1476.
6. Bode B, Beck RW, Xing D, et al. Sustained benefit of continuous glucose monitoring on A1C, glucose profiles, and hypoglycemia in adults with type 1 diabetes. Diabetes Care. 2009;32:2047-2049.
7. Beck RW, Buckingham B, Miller K, et al. Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diabetes Care. 2009;32:1947-1953.
8. Chase HP, Beck RW, Xing D, et al. Continuous glucose monitoring in youth with type 1 diabetes: 12-month followup of the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial. Diabetes Technol Ther. 2010;12:507-515.
9. Ruedy KJ, Tamborlane WV. The landmark JDRF continuous glucose monitoring randomized trials: A look back at the accumulated evidence. J Cardiovasc Transl Res. 2012; 5:380-387.
10. Beck RW, Hirsch IB, Laffel L, et al. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care. 2009;32:1378-1383.
11. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363:311-320.
12. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Sensor-augmented pump therapy for A1C reduction (STAR 3) study: Results from the 6-month continuation phase. Diabetes Care. 2011;34:2403-2405.
13. Slover RH, Welsh JB, Criego A, et al. Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. Pediatr Diabetes. 2012;13:6-11.
14. Battelino T, Liabat S, Veeze HJ, Castañeda J, Arrieta A, Cohen O. Routine use of continuous glucose monitoring in 10 501 people with diabetes mellitus. Diabet Med. 2015; 32:1568-1574.
15. Bergenstal RM, Klonoff DC, Garg SK, et al. Thresholdbased insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013;369:224-232.
16. Weiss R, Garg SK, Bode BW, et al. Hypoglycemia reduction and changes in hemoglobin A1c in the ASPIRE In-Home Study. Diabetes Technol Ther. 2015;17:542-547.
17. Yeh HC, Brown TT, Maruthur N, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: A systematic review and meta-analysis. Ann Intern Med. 2012;157:336-347.
18. Wong JC, Foster NC, Maahs DM, et al. Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry. Diabetes Care. 2014;37:2702-2709.
19. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Validation of measures of satisfaction with and impact of continuous and conventional glucose monitoring. Diabetes Technol Ther. 2010;12: 679-684.
20. Tansey M, Laffel L, Cheng J, et al. Satisfaction with continuous glucose monitoring in adults and youths with Type 1 diabetes. Diabet Med. 2011;28:1118-1122.
21. Tansey M, Weinzimer S, Beck R, et al. Extended 6-month follow-up of a randomized clinical trial to assess the efficacy and safety of real-time continuous glucose monitoring in the management of type 1 diabetes in young children aged 4 to10 years. Diabetes Care. 2013;36:e63.
22. Mauras N, Beck R, Xing D, et al.A randomized clinical trial to assess the efficacy and safety of real-time continuous glucose monitoring in the management of type 1 diabetes in young children aged 4 to 10 years. Diabetes Care. 2012;35:204-210
23. Laffel L. Improved accuracy of continuous glucose monitoring systems in pediatric patients with diabetes mellitus: Results from two studies. Diabetes Technol Ther. 2016; 18(suppl 2):S223-S233.
24. Miller KM, Foster NC, Beck RW, et al. Current state of type 1 diabetes treatment in the U.S.: Updated data from the T1D Exchange clinic registry. Diabetes Care. 2015;38:971-978.
25. Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA. The T1D Exchange clinic registry. J Clin Endocrinol Metab. 2012;97:4383-4389.
26. Leinung M, Nardacci E, Patel N, Bettadahalli S, Paika K, Thompson S. Benefits of short-term professional continuous glucose monitoring in clinical practice. Diabetes Technol Ther. 2013;15:744-747.
27. Munshi MN, Segal AR, Suhl E, et al. Frequent hypoglycemia among elderly patients with poor glycemic control. Arch Intern Med. 2011;171:362-364.
28. Allen NA, Fain JA, Braun B, Chipkin SR. Continuous glucose monitoring counseling improves physical activity behaviors of individuals with type 2 diabetes: A randomized clinical trial. Diabetes Res Clin Pract. 2008;80:371-379.
29. Gehlaut RR, Dogbey GY, Schwartz FL, Marling CR, Shubrook JH. Hypoglycemia in type 2 diabetes-more common than you think: A continuous glucose monitoring study. J Diabetes Sci Technol. 2015;9:999-1005.
30. Poolsup N, Suksomboon N, Kyaw AM. Systematic review and meta-analysis of the effectiveness of continuous glucose monitoring (CGM) on glucose control in diabetes. Diabetol Metab Syndr. 2013;5:39.
31. Vigersky RA, Fonda SJ, Chellappa M, Walker MS, Ehrhardt NM. Short-A nd long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. Diabetes Care. 2012;35:32-38.
32. Murphy HR, Rayman G, Lewis K, et al. Effectiveness of continuous glucose monitoring in pregnant women with diabetes: Randomised clinical trial. BMJ. 2008;337:a1680.
33. Bode BW, Schwartz S, Stubbs HA, Block JE. Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: Normative values. Diabetes Care. 2005;28:2361-2366.
34. Sands AT, Zambrowicz BP, Rosenstock J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care. 2015;38:1181-1188.
35. Ma Z, Chen R, Liu Y, Yu P, Chen L. Effect of liraglutide vs. NPH in combination with metformin on blood glucose fluctuations assessed using continuous glucose monitoring in patients with newly diagnosed type 2 diabetes. Int J Clin Pharmacol Ther. 2015;53:933-939.
36. Mazze R, Strock E, Morgan B, Wesley D, Bergenstal R, Cuddihy R. Diurnal glucose patterns of exenatide once weekly: A 1-year study using continuous glucose monitoring with ambulatory glucose profile analysis. Endocr Pract. 2009;15:326-334.
37. Hay LC, Wilmshurst EG, Fulcher G. Unrecognized hypo-A nd hyperglycemia in well-controlled patients with type 2 diabetes mellitus: The results of continuous glucose monitoring. Diabetes Technol Ther. 2003;5:19-26.
38. Zalzali M, Houdelet-Guerinot V, Socquard E, Thierry A, Delemer B, Lukas-Croisier C. Continuous glucose monitoring and hypoglycemia unawareness in type 1 diabetes: A pilot study. Minerva Endocrinol. 2015 July 10 [Epub ahead of print].
39. Chamberlain JJ, Dopita D, Gilgen E, Neuman A. Impact of frequent and persistent use of continuous glucose monitoring (CGM) on hypoglycemia fear, frequency of emergency medical treatment, and SMBG frequency after one year. J Diabetes Sci Technol. 2015;10:383-388.
40. Hommel E, Olsen B, Battelino T, et al. Impact of continuous glucose monitoring on quality of life, treatment satisfaction, and use of medical care resources: Analyses from the SWITCH study. Acta Diabetol. 2014;51:845-851.
41. Joubert M, Fourmy C, Henri P, Ficheux M, Lobbedez T, Reznik Y. Effectiveness of continuous glucose monitoring in dialysis patients with diabetes: The DIALYDIAB pilot study. Diabetes Res Clin Pract. 2015;107:348-354.
42. Ozieh MN, Bishu KG, Dismuke CE, Egede LE. Trends in health care expenditure in U.S. adults with diabetes: 2002-2011. Diabetes Care. 2015;38:1844-1851.
43. Geller AI, Shehab N, Lovegrove MC, et al. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. JAMA Intern Med. 2014;174:678-686.
44. Quilliam BJ, Simeone JC, Ozbay AB, Kogut SJ. The incidence and costs of hypoglycemia in type 2 diabetes. Am J Manag Care. 2011;17:673-680.
45. Umpierrez G, Korytkowski M. Diabetic emergencies-ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol. 2016;12:222-232.
46. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32:1335-1343.
47. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
48. Bronstone A, Graham C. The potential cost implications of averting severe hypoglycemic events requiring hospitalization in high-risk adults with type 1 diabetes using real-time continuous glucose monitoring. J Diabetes Sci Technol. 2016 February 15 [Epub ahead of print].
49. Ly TT, Brnabic AJ, Eggleston A, et al. A cost-effectiveness analysis of sensor-augmented insulin pump therapy and automated insulin suspension versus standard pump therapy for hypoglycemic unaware patients with type 1 diabetes. Value Health. 2014;17:561-569.
50. Huang ES, O'Grady M, Basu A, et al. The cost-effectiveness of continuous glucose monitoring in type 1 diabetes. Diabetes Care. 2010;33:1269-1274.
51. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule Med Care. 2008;46:349-356.
52. National Institutes of Health. Clinicaltrials.gov. A trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with type 1 diabetes (REPLACE-BG). Bethesda, MD: National Institutes of Health; 2016. Available at: Https://clinicaltrials. gov/ct2/show/NCT02258373. Accessed June 14, 2016.
53. Rodbard D. Display of glucose distributions by date, time of day, and day of week: New and improved methods. J Diabetes Sci Technol. 2009;3:1388-1394.
54. Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: The ambulatory glucose profile. J Diabetes Sci Technol. 2013; 7:562-578.
55. Garg S, Jovanovic L. Relationship of fasting and hourly blood glucose levels to HbA1c values: Safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor. Diabetes Care. 2006;29:2644-2649.
56. Bailey TS, Zisser HC, Garg SK. Reduction in hemoglobin A1C with real-time continuous glucose monitoring: Results from a 12-week observational study. Diabetes Technol Ther. 2007;9:203-210.
57. Kohnert KD, Vogt L, Augstein P, et al. Relationships between glucose variability and conventional measures of glycemic control in continuously monitored patients with type 2 diabetes. Horm Metab Res. 2009;41:137-141.
58. Kovatchev BP, Cox DJ, Gonder-Frederick LA, Young-Hyman D, Schlundt D, Clarke W. Assessment of risk for severe hypoglycemia among adults with IDDM: Validation of the low blood glucose index. Diabetes Care. 1998; 21:1870-1875.
59. Fabris C, Patek SD, Breton MD. Are risk indices derived from CGM interchangeable with SMBG-based indices J Diabetes Sci Technol. 2015;10:50-59.
60. Kovatchev BP, Cox DJ, Gonder-Frederick LA, Clarke W. Symmetrization of the blood glucose measurement scale and its applications. Diabetes Care. 1997;20:1655-1658.
61. Kovatchev BP, Otto E, Cox D, Gonder-Frederick L, Clarke W. Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care. 2006;29:2433-2438.
62. Mazze RS, Lucido D, Langer O, Hartmann K, Rodbard D. Ambulatory glucose profile: Representation of verified self-monitored blood glucose data. Diabetes Care. 1987; 10:111-117.
63. Welsh JB, Myers SJ, Uhrinak AN, Kaufman FR, Lee SW. User acceptability and perceived benefits of new reports in CareLink Pro 3.0 Therapy Management Software for Diabetes. J Diabetes Sci Technol. 2012;6:481-482.
64. Kovatchev B, Umpierrez G, DiGenio A, Zhou R, Inzucchi SE. Sensitivity of traditional and risk-based glycemic variability measures to the effect of glucoselowering treatment in type 2 diabetes mellitus. J Diabetes Sci Technol. 2015;9:1227-1235.
65. Welsh JB, Kannard B, Nogueira K, Kaufman FR, Shah R. Insights from a large observational database of continuous glucose monitoring adoption, insulin pump usage and glycemic control: The CareLink database. Pediatr Endocrinol Rev. 2010;(7 suppl 3):413-416.
66. Ginsberg BH. Factors affecting blood glucose monitoring: Sources of errors in measurement. J Diabetes Sci Technol. 2009;3:903-913.
67. Bailey T, Bode BW, Christiansen MP, Klaff LJ, Alva S. The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol Ther. 2015; 17:787-794.